Aurum Biosciences Ltd
Aurum Biosciences is developing ABL-101, an injectable therapeutic designed to protect tissue and improve outcomes in patients with Acute Ischemic Stroke and Spinal Cord Injury by enhancing oxygen delivery beyond clots and preserving blood flow. This platform technology also integrates with MRI imaging for diagnostic purposes, addressing critical gaps in treatment options for these high-unmet medical needs.
- Biotechnology
Funding
Raised to date
$928.4KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acute Ischemic Stroke (AIS) and Spinal Cord Injury (SCI) lack effective treatments to protect tissue and improve outcomes by enhancing oxygen delivery beyond clots and preserving blood flow. The majority of AIS patients are unsuitable for existing treatments, and there is currently no treatment capable of reversing damage to the spinal cord following SCI.
Solution
Aurum Biosciences is developing ABL-101, an injectable therapeutic designed to address the unmet needs in AIS and SCI. ABL-101 aims to deliver oxygen beyond clots in AIS, protecting tissue and increasing the opportunity to treat the stroke with other options. In SCI, ABL-101 has the potential to protect tissue damaged by disrupted blood flow and improve functional outcomes. The ABL-101 platform technology also integrates with MRI imaging for diagnostic purposes in stroke.
Target Audience
The primary target audience includes patients with Acute Ischemic Stroke (AIS) and Spinal Cord Injury (SCI), as well as medical professionals involved in their care.
Features
- Injectable therapeutic for Acute Ischemic Stroke (AIS) and Spinal Cord Injury (SCI)
- Designed to enhance oxygen delivery beyond clots in AIS
- Aims to protect tissue and improve functional outcomes in SCI by preserving blood flow
- Integrates with MRI imaging for diagnostic purposes in stroke
- Patented ABL 101 platform technology